Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 56 INDUSTRY 30 NIH 8 NETWORK 1 INDIV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2 Gastrointestinal 2 Plasma cell 1 Lymphoid 1 Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Cyclophosphamide 42 Docetaxel 33 Paclitaxel 31 Tamoxifen 29 Doxorubicin 29 Trastuzumab 25 Radiotherapy 21 Epirubicin 16 Letrozole 15 Anastrozole 12 exemestane 11 Fluorouracil 11 Capecitabine 10 Bevacizumab 10 palbociclib 9 Immunohistochemistry 9 Fulvestrant 9 Filgrastim 9 Lapatinib 8 Zoledronic Acid 7 Methotrexate 7 Magnetic Resonance Spectroscopy 7 Gene Expression Profiling 7 pertuzumab 6 Triptorelin Pamoate 6 Taxes 6 Surgical Procedures, Operative 6 Microarray Analysis 6 Goserelin 6 Chemotherapy, Adjuvant 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × olaparib × Breast × Clear all

NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡